Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 368,451,040
  • Shares Outstanding, K 1,768,169
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,075 M
  • EBITDA $ 24,061 M
  • 60-Month Beta 0.38
  • Price/Sales 6.04
  • Price/Cash Flow 13.80
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 34.15% (+1.15%)
  • Historical Volatility 25.73%
  • IV Percentile 97%
  • IV Rank 76.60%
  • IV High 38.94% on 04/21/25
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 4) 5.02 (2.46%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 11,814
  • Volume Avg (30-Day) 12,609
  • Put/Call OI Ratio 1.10
  • Today's Open Interest 227,998
  • Open Int (30-Day) 231,558
  • Expected Range 198.70 to 208.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $2.62
  • Number of Estimates 4
  • High Estimate $2.72
  • Low Estimate $2.58
  • Prior Year $2.46
  • Growth Rate Est. (year over year) +6.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
201.66 +1.01%
on 04/07/26
220.45 -7.59%
on 04/01/26
-1.36 (-0.66%)
since 03/20/26
3-Month
201.66 +1.01%
on 04/07/26
237.11 -14.09%
on 03/04/26
-10.33 (-4.83%)
since 01/20/26
52-Week
168.54 +20.87%
on 04/21/25
244.81 -16.79%
on 10/01/25
+30.72 (+17.76%)
since 04/17/25

Most Recent Stories

More News
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada

TORONTO , April 20, 2026 /CNW/ - Today, AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced the expansion of its partnership with BioLabs by becoming...

ABBV : 203.71 (-2.24%)
Only 3 Dividend Kings Passed This Brutal Screen. They Could Pay You Well for Years to Come.

Three Dividend Kings with 50+ years of raises combine reliable income, solid growth, and analyst support, making them stand out in a shaky market.

PH : 996.44 (+0.77%)
ABBV : 203.71 (-2.24%)
NUE : 202.26 (+3.26%)
1 Value Stock Worth Your Attention and 2 That Underwhelm

1 Value Stock Worth Your Attention and 2 That Underwhelm

ASGN : 40.04 (+1.52%)
ABBV : 203.71 (-2.24%)
REYN : 21.63 (-3.22%)
Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

IRVINE, Calif. , April 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is...

ABBV : 203.71 (-2.24%)
2 S&P 500 Stocks with Solid Fundamentals and 1 We Brush Off

2 S&P 500 Stocks with Solid Fundamentals and 1 We Brush Off

KDP : 26.50 (-0.11%)
ADM : 68.37 (+1.98%)
ABBV : 203.71 (-2.24%)
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?

Revolution Medicines stock rallies on impressive daraxonrasib Phase 3 results. Here’s why RVMD shares may sustain the momentum moving forward.

MRK : 117.10 (-1.65%)
ABBV : 203.71 (-2.24%)
RVMD : 146.23 (-1.61%)
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

NORTH CHICAGO, Ill. , April 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the...

ABBV : 203.71 (-2.24%)
3 Market-Beating Stocks with Competitive Advantages

3 Market-Beating Stocks with Competitive Advantages

PLMR : 132.41 (-0.11%)
AMP : 456.59 (+0.09%)
ABBV : 203.71 (-2.24%)
3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

These three Dividend Aristocrats offer yields above 3% and a history of consistent dividend growth, making them strong choices to help stay ahead of inflation.

CVX : 183.25 (-0.40%)
AMCR : 41.65 (-0.69%)
ABBV : 203.71 (-2.24%)
3 Companies Aggressively Raising Dividends While Others Play Defense

A strong dividend stock may not only pay a healthy distribution, but also be able to continue to grow its payouts thanks to steady, strong business.

FIX : 1,680.09 (+1.79%)
MPWR : 1,490.86 (+1.53%)
ABBV : 203.71 (-2.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 212.57
2nd Resistance Point 210.45
1st Resistance Point 207.08
Last Price 203.71
1st Support Level 201.59
2nd Support Level 199.47
3rd Support Level 196.10

See More

52-Week High 244.81
Fibonacci 61.8% 215.67
Fibonacci 50% 206.67
Last Price 203.71
Fibonacci 38.2% 197.68
52-Week Low 168.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.